<abstract xmlns="http://www.w3.org/1999/xhtml">

<bold>Objective</bold>: The primary objective of this study was to investigate the association between biomarkers of iron metabolism and metabolic dysfunction-associated fatty liver disease in individuals with type 2 diabetes and non-diabetic individuals compared to a control group. We also examined the possible association between estimated liver fibrosis and serum ferritin levels in all three groups.
<bold>Methods</bold>: We conducted a descriptive, cross-sectional, comparative study involving subjects diagnosed with diabetes and/or metabolic dysfunction-associated fatty liver disease from an outpatient diabetology clinic and two general practices in Târgu Mureș. The patient population was divided into 3 groups: first group including diabetic patients suffering from fatty liver disease, second group including patients without fatty liver disease and third group with non-diabetic patients suffering from fatty liver disease. We compared the three groups based on specific laboratory tests.
<bold>Results</bold>: Patients with fatty liver disease had significantly higher ferritin and transferrin saturation levels than non-fatty liver disease sufferers (p&lt;0.05). Transferrin saturation of the first group was significantly (p&lt;0.05) higher compared to the non-diabetic fatty liver disease group. Ferritin correlated well with Fibrosis-4 index level (τ= 0.193, p&lt;0.01) considering the whole sample and especially in the first group.
<bold>Conclusions</bold>: In our study, there was a clear association between higher ferritin levels and the presence of metabolic dysfunction-associated fatty liver disease. The higher transferrin saturation observed in diabetic patients suffering from metabolic dysfunction-associated fatty liver disease may indicate the possible etiological significance of iron overload. Higher ferritin levels in diabetes increase the risk of liver fibrosis.
</abstract>

Objective: The primary objective of this study was to investigate the association between biomarkers of iron metabolism and metabolic dysfunction-associated fatty liver disease in individuals with type 2 diabetes and non-diabetic individuals compared to a control group. We also examined the possible association between estimated liver fibrosis and serum ferritin levels in all three groups.
Methods: We conducted a descriptive, cross-sectional, comparative study involving subjects diagnosed with diabetes and/or metabolic dysfunction-associated fatty liver disease from an outpatient diabetology clinic and two general practices in Târgu Mureș. The patient population was divided into 3 groups: first group including diabetic patients suffering from fatty liver disease, second group including patients without fatty liver disease and third group with non-diabetic patients suffering from fatty liver disease. We compared the three groups based on specific laboratory tests.
Results: Patients with fatty liver disease had significantly higher ferritin and transferrin saturation levels than non-fatty liver disease sufferers (p<0.05). Transferrin saturation of the first group was significantly (p<0.05) higher compared to the non-diabetic fatty liver disease group. Ferritin correlated well with Fibrosis-4 index level (τ= 0.193, p<0.01) considering the whole sample and especially in the first group.
Conclusions: In our study, there was a clear association between higher ferritin levels and the presence of metabolic dysfunction-associated fatty liver disease. The higher transferrin saturation observed in diabetic patients suffering from metabolic dysfunction-associated fatty liver disease may indicate the possible etiological significance of iron overload. Higher ferritin levels in diabetes increase the risk of liver fibrosis.

Iron metabolism and metabolic dysfunction-associated fatty liver disease

George Emil Palade University of Medicine

Acta Marisiensis - Seria Medica

This work is licensed under the Creative Commons Attribution 4.0 International License.

{"article-title":"Iron metabolism and metabolic dysfunction-associated fatty liver disease"}

Objective: The primary objective of this study was to investigate the association between biomarkers of iron metabolism and metabolic dysfunction-associated...

Iron metabolism and metabolic dysfunction-associated fatty liver disease

Publié en ligne: 28 sept. 2023

Pages: 182 - 186

Reçu: 05 juin 2023

Accepté: 15 août 2023

DOI: https://doi.org/10.2478/amma-2023-0031

Mots clés
fatty liver, iron biomarkers, liver fibrosis, metabolic syndrome

© 2023 Zoltán-Zsombor Élthes et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Iron metabolism and metabolic dysfunction-associated fatty liver disease

Publié en ligne: 28 sept. 2023

Pages: 182 - 186

Reçu: 05 juin 2023

Accepté: 15 août 2023

DOI: https://doi.org/10.2478/amma-2023-0031

Mots clésfatty liver, iron biomarkers, liver fibrosis, metabolic syndrome

© 2023 Zoltán-Zsombor Élthes et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Mots clés
fatty liver, iron biomarkers, liver fibrosis, metabolic syndrome